association of reproductive health professionals

Association of Reproductive Health Professionalswww.arhp.org

Options for Therapeutic Abortion: Manual Vacuum Aspiration and Medication Management

Expert Medical Advisory Committee• Herbert P. Brown, MD• Michelle Forcier, MD, MPH• Emily Godfrey, MD, MPH• Marji Gold, MD • Jini Tanenhaus, PA, MA

Learning Objectives• List four clinical indications for manual vacuum

aspiration (MVA)• List four factors to consider when counseling

women about MVA versus medical management of early pregnancy loss

more…

Learning Objectives (continued)

• List three conditions in a patient that should cause a provider to use caution before providing MVA or medical management of early pregnancy loss

• List at least one medication regimen used for early medication abortion

Module 1:MVA Overview

Unintended Pregnancy in the United States (2001)

Finer LB, Henshaw SK. Perspect Sex Reprod Health. 2006.

Intended

6.3 million pregnancies

Birth

Abortion

Fetal Loss

Unintended

Outcomes of Unintended PregnanciesApproximately 3 million annually in the United States

Finer LB, Henshaw SK. Perspect Sex Reprod Health. 2006.

44% BirthAbortion 42%

Miscarriage/Fetal Demise

14%

Abortions by Length of Pregnancy

Strauss LT, et al. MMWR. 2006

≤89 to 1011 to 1213 to 1516 to 20≥21

Weeks Gestation

61%18%

10%

6%

1%

4%

What Is a Manual Vacuum Aspirator?

Creinin MD, et al. Obstet Gynecol Surv. 2001.; Goldberg AB, et al. Obstet Gynecol. 2004.’ Hemlin J, et al. Acta Obstet Gynecol Scand. 2001.

Manual vacuum aspirator• Has locking valve• Is portable and reusable• Vacuum is equivalent to

electric pump• Efficacy is same as electric

vacuum (98%–99%)• Has semi-flexible plastic cannula

What Is an Electric Vacuum Aspirator?

Creinin MD, et al. Obstet Gynecol Surv. 2001.; Goldberg AB, et al. Obstet Gynecol. 2004.; Hemlin J, et al. Acta Obstet Gynecol Scand. 2001.

Electric vacuum aspirator• Uses an electric pump or

suction machine connected via flexible tubing

• Has a plastic or metal cannula

• Typically used in centralized settings with high caseloads

History of MVA

Bird ST, et al. Contraception. 2003.; Edwards J, et al. Curr Probl Obstet Gynecol Fertil. 1997.; Karman H, et al. Lancet. 1972.

1973: Helms Amendment enacted

1973: USAID sponsors Ipas

1980s: MVA marketed worldwide

1990s: MVA used in >100 countries

Comparison of EVA to MVA

Dean G, et al. Contraception. 2003.

EVA MVAVacuum Electric pump Manual aspiratorNoise Variable Quiet

Portable Not easily YesCannula 4–16 mm 4–12 mmCapacity 350–1,200 cc 60 cc

Suction Constant Decreases to 80% (50 mL) as aspirator fills

Products of Conception (POC)

Edwards J, et al. Am J Obstet Gynecol. 1997.MacIsaac L, et al. Am J Obstet Gynecol. 2000.

Procedure is complete when POC are identified

Electric Suction Machine

MVA Aspirator

Clinical Indications for MVA • Uterine evacuation in the first trimester:

▪ Induced abortion▪ Spontaneous abortion

• Incomplete medication abortion• Uterine sampling• Post-abortal hematometra

Creinin MD, et al. Obstet Gynecol Surv. 2001.; Edwards J, Creinin MD. Curr Probl Obstet Gynecol Fertil.1997.; Castleman LD et al. Contraception. 2006; MVA Label. Ipas. 2007.

Complications with MVA• Very rare • Same as EVA• May include:

▪ Incomplete evacuation▪ Uterine or cervical injury▪ Infection▪ Hemorrhage▪ Vagal reaction

MVA Label. Ipas. 2004.

Putting Abortion into Perspective…

Gold RB, Richards C. Issues Sci Technol. 1990.; Hatcher RA. Contracept Technol Update. 1998.; Mokdad AH, et al. MMWR Recomm Rep. 2003.

Incident Chance of death

Terminating pregnancy < 9 weeks 1 in 500,000

Terminating pregnancy > 20 weeks 1 in 8,000

Giving birth 1 in 7,600

Driving an automobile 1 in 5,900

Using a tampon 1 in 350,000

Post-Abortion Care

Creinin MD, et al. Obstet Gynecol Surv. 2001.; Goldberg AB, et al. Obstet Gynecol. 2004.; Hemlin J, Moller B. Acta Obstet Gynecol Scand. 2001.

• Women desiring pregnancy▪ Vitamin and diet recommendations▪ Toxic-exposure avoidance guidelines

• Women avoiding pregnancy▪ Contraceptive counseling▪ Contraception initiated on day of MVA

MVA vs. EVA Complication RatesMethods• Vacuum aspiration for abortion up to 10 wks LMP• Retrospective cohort analysis• Choice of method (MVA vs. EVA) up to physician• n = 1,002 for MVA; n = 724 for EVA • Charts reviewed for complications

Goldberg AB, et al. Obstet Gynecol. 2004.

more…

MVA vs. EVA Complication Rates (continued)


Complications

• 2.5% for MVA• 2.1% for EVA (p = 0.56)• No significant difference

more…*Elective not spontaneous studies

MVA vs. EVA Complication Rates (continued)


Choice of MVA vs EVA in procedures

• Attendings: 52% MVA

• Gyn residents: 59% MVA

• Other residents: 76% MVA (p<0.001)

*Elective not spontaneous studies

Conventional Wisdom and Abortion Care

Depineres T, Stewart F. NAF. 2002. ; Castadot RG. Fertil Steril. 1986.Edwards J, Creinin MD. Curr Probl Obstet Gynecol Fertil. 1997.

1970s

•Wait 7+ weeks for lowest risk of complications

Today

• Ultra-sensitive pregnancy tests

• POC inspection• Ultrasound• Medication abortion• MVA• No reason to wait

What Services Do You Provide?

Use index cards provided to answer the following. Do not write your name.• Does your facility currently provide vacuum

aspiration abortions before 6 weeks? ▪ Yes/No

• Are there clinical or program-related barriers to providing early abortion with vacuum aspiration? ▪ Yes/No (If yes, list the most significant barriers.)

Earlier Procedures Are Safer

Bartlet L, et al. Obstet Gynecol. 2004.

Gestational Age

Strongest risk factor for abortion-related

mortality

Abortions at <8 weeks = lowest risk of death

“…Because access to abortions even one week earlier reduces the risk of death…increased access to early abortion services may increase the proportion of abortions performed at the lower-risk, early gestational ages and help reduce maternal deaths.”

Offering Services as Early as Possible

Bartlet L, et al. Obstet Gynecol. 2004.

Early Abortion with Vacuum Aspiration

Author Date N Gestational Age Efficacy

Paul et al. 2002 1,132 (MVA+EVA) <6 98%

Edwards & Carson 1997 1,530 MVA <6 99%

Edwards & Creinin 1997 2,399 MVA <6 99%

Hemlin & Moller 2001 91 MVA <8 98%

Laufe 1977 12,888 “About 6” 98%

Baird TL, Flinn SK. 2001.; Edwards J, Carson SA. Am J Obstet Gynecol. 1997.Edwards J, Creinin MD. Curr Probl Obstet Gynecol Fertil. 1997. Hemlin J, Moller B. Acta Obstet Gynecol Scand. 2001.; Paul ME, et al. Am J Obstet Gynecol. 2002.

Early Abortion with MVA: Study • Methods

▪ 2,399 MVA procedures, < 6 weeks LMP▪ Meticulous inspection of POC immediately after

MVA• Results

▪ 99.2% effective in terminating pregnancy▪ 6 repeat aspirations (0.25%)▪ 14 ectopic pregnancies (0.6%) diagnosed and

treated

Edwards J, Creinin MD. Curr Probl OIbstet Gynecol Fertil. 1997.

Early Abortion with MVA or EVA: Study

Methods• 1,132 women, ≤ 6 weeks LMP• Of 1,093 procedures:

▪ 52% MVA▪ 40% EVA▪ 8% both

• Examination of POC immediately after procedure

Paul ME, et al. Am J Obstet Gynecol. 2002.

more…

Early Abortion with MVA or EVA: Study (continued)


more…

17 of 1,132Required re-aspiration

Results

2.3% of study population



more…

Failure rates by technique among women with follow-up (95% CI):

1.1% 2.9% 7.5%(0.4%-3.0%) (1.4%-5.7%) (2.1%-18.2%)

MVA EVA Both used


Of the 750 women with follow-up, 13 experienced other complications:• 4 incomplete abortions• 2 unrecognized ectopic pregnancies • 1 hematometra• 4 pelvic infections• 3 re-aspirations for pain and bleeding despite

negative pathology


MVA and POC: Study

• In group overall ▪ n = 1,726, up to 10 weeks LMP

• Complication rates between MVA and EVA▪ 37 patients at < 6 weeks’ gestation▪ In 35 of 37, provider chose MVA ▪ No re-aspirations needed in patients < 6 weeks


more…

MVA and POC: Study (continued)

“…Significantly more re-aspirations for inability to accurately identify the pregnancy occurred in electric group.”

Goldberg AB et al. Obstet Gynecol, 2004


Safety and Efficacy: Family Practice Office

Methods• Abortion using MVA, <12 weeks LMP• Retrospective chart review, N = 1,677 • 60% performed by residents under supervision• 40% performed by attendings

Westfall JM, et al. Arch Fam Med. 1998.

more…

Safety and Efficacy: Family Practice Office (continued)

Results• 99.5% effective• 1.3% minor complications• No hospitalizations

Westfall JM, et al. Arch Fam Med. 1998.

Patient Satisfaction

• Both EVA and MVA groups were highly satisfied

• No differences in:▪ Pain▪ Anxiety▪ Bleeding▪ Acceptability ▪ Satisfaction

• More EVA patients were bothered by noiseBird ST, et al. Contraception. 2003.; Dean G, et al. Contraception. 2003.; Edelman A, et al. Am J Obstet Gynecol. 2001.

MVA Safety and Efficacy: Summary

• MVA is simple▪ Easily incorporated into office setting

• Training/Practice Issues▪ Expanding pain management options▪ Ultrasound as needed▪ No sharp curettage▪ Patient-provider interaction▪ Identifying products of conception▪ Instrument processing for multiple use

MVA in Office Settings• Safety and efficacy equivalent to EVA• Portable• Simple• Low cost• Small and quiet


Beneficial to incorporate MVA servicesinto the office setting.

Module 2:MVA Procedure

MVA Steps

Gather required supplies

Charge aspirator

Stabilize and anesthetize cervix

Insert cannula

Empty uterus

After counseling and support …

MVA Instruments

Steps for Performing MVA

A step-by-step, one- page poster is

available from the manufacturer to guide clinicians

through the procedure

MVA and Pain

Pain is made worse by:• Fearfulness• Anxiety• Depression

Belanger E, et al. Pain. 1989.; Smith GM, et al. Am J Obstet Gynecol. 1979.Hansen GR, Streltzer J. Emerg Med Clin N Am. 2005.

Effective Pain Management• Respectful, informed, and supportive staff• Warm, friendly environment• Gentle operative technique• Women’s involvement• Effective pain medications

Pain Management Philosophies • Minimize risk/maximize benefit• Take away all pain/all feeling• Get through it

Pain Management Techniques

Lichtengerg ES, et al. Contraception. 2001.Good M, et al. Pain Manag Nurs. 2002.

Local

General or nitrous

Local + IV

10%

32% 58%

With addition of:• Focused breathing: 76%• Visualization: 31%• Localized massage: 14%

Paracervical Block

Regular InjectionDeep Injection

Castleman L, Mann C. 2002. Maltzer DS, et al. 1999.

Efficacy of Ancillary Anesthesia

• Importance of psychological preparation and support

• Music as analgesia for abortion patients receiving paracervical block ▪ 85% who wore headphones rated pain as “0,”

compared with 52% of controls• Verbicaine (“Vocal Local”)/Distraction

Therapy

Shapiro AG, Cohen H. Contraception. 1975. Stubblefield PG.Suppl Int J Gynecol Obstet. 1989.

Sharp Curettage and Pain

• Often requires increased dilatation

• Often painful• More difficult to

reduce anesthesia

Forna F, Gulmezoglu AM. Cochrane Library. 2002.

Sharp Curettage and MVA• Generally not indicated • Not routinely recommended after MVA

WHO. 2003

more…

Sharp Curettage and MVA (continued)

“…Health managers and policy makers should make all possible efforts to replace sharp curettage (D&C) with vacuum aspiration.”

WHO, 2003

WHO, Safe Abortion: Technical and Policy Guidance for Health Systems. 2003.

Pain Management Tips

Affirm patient’s viewpoint

Provide medical information

Avoid glib reassurances

Tell patient her fears are common

Help patient differentiate pain

Pain Management Options: Summary• More to pain management than avoiding pain• No pain panacea• Women should be involved• Curette check increases pain; usually not needed• Pre-procedure preparation and psychological

support can reduce anxiety and improve overall experience

Who Can Provide MVA in the United States?

• All physicians • All mid-level providers including:

▪ Physician assistants▪ Nurse practitioners ▪ Nurse midwives

• Research your state’s individual laws, rulings, and professional scopes of practice

more…

Who Can Provide MVA in the United States? (continued)

Legal use may depend upon specific diagnosis of patient:

• Incomplete abortion• Prolonged uterine bleeding• Endometrial biopsy• Elective abortion where legal

MVA Training Organizations• Association of Reproductive Health Professionals

(ARHP)• Clinician Training Initiative (CTI)—Planned

Parenthood of New York City (PPNYC)• National Abortion Federation (NAF)• Planned Parenthood® Federation of America (PPFA)• Ipas• Physicians for Reproductive Choice and Health

(PRCH)

Facilities Needed for MVA

• Privacy for counseling • Procedure room

▪ Exam table▪ Space for supplies,

processing instruments, and examining products of conception

Medications and Supplies Needed for MVA

• Analgesia• Anesthetic• Silver nitrate or ferric subsulfate• Uterotonic agent• Rhogam

more…

Medications and Supplies Needed for MVA (continued)

• Urine pregnancy tests• Emergency cart• Pharmacologic agents for cervical ripening

(optional)

Equipment Needed for MVA

Procedure• Aspirators• Cannulae• Speculae• Sharp-toothed and/or atraumatic tenaculae

more…

Equipment Needed for MVA (continued)

Procedure• Antiseptic solution• Mechanical dilators• 20-cc syringe for local anesthesia

more…

Equipment Needed for MVA (continued)

Equipment for POC Exam after MVA

Tissue examination• Basin for POC• Fine-mesh kitchen strainer• Back light or enhanced light• Tools to grasp tissue and POC• Specimen containers

Hyman AG, Castleman L. Ipas. 2005

Ultrasound and MVA

• Not required for MVA

• Used by some providers routinely

• Use contingent on provider preference and experience

Word Health Organization. 2003.

Women’s Access to Care

Leonard A, Winkler J. Adv Abortion Care. 1991.

Incorporating MVA Into Practice

What does it take to incorporate the MVA

procedure into a clinical practice?

MVA Staffing and Facilities Requirements: Summary• All physicians and advanced practice clinicians in

many states can provide MVA• Facilities requirements include medication,

supplies, equipment, and instruments• Use of ultrasound is not required

MVA Patient Intake and Counseling

Contraindications to MVA • First-trimester induced abortion—NONE• First-trimester spontaneous abortion—NONE• Completion of incomplete abortion—NONE• Suspected pregnancy—endometrial biopsy should

NOT be performed

Ipas. 2007.

Use Caution in Women with…• Uterine anomalies• Coagulation problems• Active pelvic infection • Extreme anxiety• Any condition causing the patient to be medically

unstable

Ipas. 2007.

Patient Intake Steps for MVA• Medical history• Lab work, including -hCG• Determine gestational age• Educate about procedure and

pain management• Informed consent • Discuss contraception

MacIsaac L, Darney P. Am J Obstet Gynecol. 2000. World Health Organization. 2003.

Counseling for MVA

Effective counseling occurs before, during, and after the procedure• Woman-centered • Structured completely

around the women’s needs and concerns

more…Breitbart V, Repass DC. J Am Med Womens Assoc. 2000.; Hogue CJ, et al. Epidemiol Rev. 1982; Steward FH, et al. 2004. Hyman AG, Castleman L. 2005

Counseling for MVA (continued)

• Prepare women for procedure-related effects

• Address women’s concerns about future desired pregnancies

more…Breitbart V, Repass DC. J Am Med Womens Assoc. 2000.; Hogue CJ, et al. Epidemiol Rev. 1982; Steward FH, et al. 2004. Hyman AG, Castleman L. 2005

Counseling for MVA (continued)

Picker Institute. 1999.

Quality of counseling

Patient satisfaction with care

Post-Procedure Care

• Observe for complications▪ Bleeding ▪ Pain

• Monitor pain and treat accordingly• Monitor vital signs• Check bleeding and pain

more…

Post-Procedure Care (continued)

• Give instructions for aftercare/follow-up• Discuss contraception, if appropriate• Discharge patient

▪ Tolerates oral intake (general anesthesia only)▪ Vital signs are normal▪ Bleeding is minimal

Lichtenberg ES, Shott S. Obstet Gynecol. 2003.

Instructions for Aftercare• Warning signs to call a clinician• Pain management options• Prophylactic antibiotics

▪ Many regimens effective• When to return to normal

activities

Lichtenberg ES, Shott S. Obstet Gynecol. 2003.

When Women Should Contact Clinician• Heavy bleeding with dizziness, lightheadedness• Worsening pain not relieved with medication• Flu-like symptoms lasting >24 hours• Fever or chills• Syncope• Any questions

Contraception After MVAOvulation may occur within 7–10 days post-MVA• Dispense EC with instructions for use• Can start hormonal contraceptives immediately• Can insert IUD immediately post-procedure

more…

Contraception After MVA (continued)

• Tubal ligation can be performed post-procedure or scheduled; develop interim contraception plan

• Use barrier contraceptive with first and subsequent intercourse

Module 3:Medication Abortion

Medication Abortion

Jones RK, Henshaw SK. Perspet Sex Reprod Health. 2002.

Medication Abortion Regimens

• FDA-approved regimen▪ Mifepristone 600 mg PO followed by misoprostol

400 µg orally 48 hours later• Evidence-based regimens

▪ Mifepristone 200 mg followed by 600 µg of oral misoprostol

▪ Mifepristone 200 mg followed by 800 µg of vaginal misoprostol

WHO Task Force. BJOG. 2000; Peyron R, et al. N Engl J Med. 1993.; Spitz IM, et al. N Eng J Med. 1998.; Aubény E, et al. Int J Fertil Menopausal Stud. 1995; Kahn JG, et al. Contraception. 2000.

Protocols – Medication AbortionFDA Approved Regimen(Based on evidence up to 1996)

Alternative Evidence-Based Regimen(Based on current evidence)

Gestational age:Up to 49 days after first day of last period



Mifepristone 600 mg. (swallowed in the office)

Mifepristone 200 mg.(swallowed in the office)

Mifepristone 200 mg.(swallowed in the office)

Misoprostol 400 mcg. Oral useSwallowed in the office48 hours after taking mifepristone

Misoprostol 800 mcg. Buccal useUsed at home 24-48 hours after taking mifepristonePut in the cheek to melt

Misoprostol 800 mcg. Vaginal useUsed at home 6–72 hours after taking mifepristonePut in the vagina

Office follow-up 10–15 days after taking mifepristone



3 office visits 2 office visits 2 office visits

RHEDI. Montifiore Medical Center. www.rhedi.org

Evidence-Based Regimens• 200-mg dose of mifepristone• Buccal or vaginal administration of misoprostol• Home use of misoprostol• Flexibility in day of vaginal misoprostol use• Flexibility in initial follow-up evaluation

Kahn JG. Contraception. 2000.; Middleton T. Contraception. 2005.; El-Rafaey H. N Engl J Med. 1995.; Schaff EA. J Fam Pract. 1997.; Schaff EA. Contraception. 1999.; Schaff EA. JAMA. 2000.; Schaff EA. Contraception. 2001.; Schaff EA. Contraception. 2000.

Medication Abortion Efficacy

Gestational age (weeks)

Complete abortion rate (%)

Time to expulsion (after misoprostol)

< 49 91–97 49%–61% within 4 hours

< 56 83–95 87%–88% within 24 hours

< 63 88

600 mg oral mifepristone/400 mcg oral misoprostol

WHO Task Force. BJOG. 2000.; Peyron R, et al. N Engl J Med. 1993. Spitz IM, et al. N Engl J Med. 1998; Winikoff B, et al. Am J Obstet Gynecol. 1997.





< 49 96–97 56% within 4 hours

50–63 89–93

200 mg oral mifepristone/600 mcg oral misoprostol

McKinley C, et al. Hum Reprod. 1993.Baird DT, et al. Hum Reprod. 1995.

Plasma Concentration of Misoprostol

Wiehe E, et al. Obstet Gynecol. 2002.; el-Refaey H, et al. N Engl J Med. 1995.Schaff EA, et al. Contraception. 2001; Zieman M, et al. Obstet Gynecol. 1997; Fjerstad, 2006.

Pla

sma

mis

opro

stol

con

cent

ratio

n (p

g/m

L)

oral (n = 10)

vaginal (n = 10)

050

100150200250300350

60 min 120 min 180 min 240 min





<56 98 93% within 4 hours

<63 95

600 mg oral mifepristone/800 mcg vaginal misoprostol

Schaff EA, et al. Contraception. 1999.el-Refaey H, et al. N Engl J Med. 1995.





< 49 98 94% within 6 hours

< 56 97–98

< 63 98

200 mg oral mifepristone/800 mcg vaginal misoprostol

Ashok PW, et al. Hum Reprod. 1998.Schaff EA, et al. Contraception. 1999.

Medication Abortion Safety Issues• Atypical presentation of infection and sepsis• Prolonged heavy vaginal bleeding

Danco Laboratories. 2005.; FDA. 2006.Green MF. N Engl J Med. 2005.

Do Not Use in Women with…• Confirmed or suspected ectopic pregnancy• IUD in place• Long-term corticosteroid use• Hemorrhagic disorders or inherited porphyrias

Danco Laboratories. 2005.

more…

Do Not Use in Women with…(continued)

• Concurrent anticoagulant use• Chronic adrenal failure• Allergy to mifepristone, misoprostol, or other

prostaglandin

Danco Laboratories. 2005.

Patient Intake Exercise

Patient Intake Steps for Medication Abortion• Medical history• Lab work• Determine gestational age• Educate about procedure and pain management• Informed consent and patient agreement• Medication guide • Discuss contraception

Danco Laboratories. 2005. World Health Organization. 2003.

Pain Management• Ibuprofen or acetaminophen initially• Oral narcotics if necessary

Grimes DA, Creinin MD. Ann Intern Med. 2004.

When Women Should Contact Clinician• Heavy bleeding with dizziness, lightheadedness• Worsening pain not relieved with medication• Flu-like symptoms lasting >24 hours• Fever or chills• Syncope• Any questions

FDA. 2006.

Clostridium sordelli Infection

• Fever may not develop• Consider other signs of infection:

▪ Weakness▪ Nausea▪ Vomiting▪ Diarrhea

FDA. 2006.

Follow-up After Medication Abortion

• Assess completion of abortion by▪ Patient history▪ Serial HCGs or sonography▪ Speculum and/or bimanual exam as indicated

• Documentation of missed follow-up• If procedure is incomplete or unsuccessful,

MVA can be used for retained POC

Contraception After Medication Abortion• Ovulation may occur within 7–10 days after abortion• Dispense EC with instructions for use• Can start hormonal contraceptives before follow-up• Can insert IUD when abortion is confirmed

Stewart FH, et al. 2004.

Becoming a Medication Abortion Provider

• Apply to distributor to obtain mifepristone: www.earlyoptionpill.com

• Training available through National Abortion Federation: www.prochoice.org

Grimes DA, Creinin MD. Ann Intern Med. 2004.

Module 4: Counseling Women on MVA Versus Medication Abortion

Factors to Consider• Duration of pregnancy• Efficacy• Safety• Side effects• Use of anesthesia• Location• Time required

Options for Terminating Pregnancy

0 12 24 Weeks LMP

Dilation and Evacuation

Electric Vacuum Aspiration

Manual Vacuum Aspiration

Methotrexate/Misoprostol

Mifepristone/Misoprostol

Amniocentesis/AmnioinfusionUterotonic/Hypertonic

Stewart FH, et al. 2004.

Efficacy of Abortion Options

Surgical and medication abortion are highly effective

0 1 2 3 4 5 6 7 8 9 10 Weeks LMP

Manual vacuum aspiration 99%

Medication abortion (oral)91%–97% 88%

98%Medication abortion

(vaginal)Edwards J, Creinin MD. Curr Probl Obstet Gynecol Fertil. 1997.Goldberg AB, et al. Obstet Guynecol. 2004; WHO Task Force. BJOG. 2000.Ashok PW, et al. Hum Reprod. 1998.

Safety of Abortion

MVA

• Uterine or cervical injury

• Infection

Surgical and medication abortion are low risk

Medication

• Infection• Heavy bleeding

Stewart FH, et al. 2004.; Danco Laboratories. 2005.FDA. 2006.; Green MF. N Engl J Med. 2005.

Expectations

MVA

• Cramping• Bleeding

Usually subside quickly

Medication

• Cramping• Bleeding• Nausea/vomiting• Diarrhea• Fever/chills• Fatigue

Grimes DA, Creinin MD. Ann Intern Med. 2004.NAF. 2006.

Location: Where Abortion Occurs

MVA

• Hospital or office setting

Medication

• Begins in hospital/office

• Occurs at home

NAF. 2006.

Time Required for Abortion

MVA

• Complete within minutes

• 1 visit to provider

Medication• Complete within

24–48 hours• 2 visits to provider

(evidence-based)

NAF. 2006.

Advantages of Abortion Options

Stewart FH, et al. 2004.NAF. 2006.

MVA• Quicker• Woman less

involved • More certain

Medication• More natural• More private• Usually avoids

surgery

Disadvantages of Abortion Options

Stewart FH, et al. 2004.NAF. 2006.

MVA• Invasive• Less private• Small risk of

injury or infection

Medication• Waiting, uncertainty• Longer bleeding,

cramping, nausea• Additional clinic visit

Appendix

Expert Medical Advisory CommitteeHerbert P. Brown, MD Clinical Associate Professor of Ob/GynUniversity of Texas Health Science CenterSan Antonio, TX

more…

Michelle Forcier, MD, MPH Adjunct Assistant Clinical Professor of Pediatrics University of North Carolina School of Pediatrics and Family Medicine and Duke University School of Pediatrics Chapel Hill, NC

Emily Godfrey, MD, MPH Assistant Professor, Department of Family Medicine University of Illinois at Chicago Chicago, IL

Expert Medical Advisory Committee (continued)

Marji Gold, MD Professor of Family and Social MedicineAlbert Einstein College of MedicineBronx, NY

Jini Tanenhaus, PA, MA Associate Vice President, Clinician Training InitiativePlanned Parenthood of New York CityNew York, NY

association of reproductive health professionals

Documents

md professor of family

clinical indications

md jini tanenhaus

therapeutic abortion

medical students

john merck fund

original funding

original content